This is an octapeptide analogue of somatostatin with similar properties but a longer duration of action.

Indications: symptomatic treatment of diarrhoea associated with carcinoid tumour, treatment of profuse diarrhoea associated with vasoactive intestinal peptide tumours (VIPoma); reduce blood levels of growth hormone in acromegaly.

Cautions: monitored for signs of tumour expansion (visual field defects), ultrasound of gall bladder is recommended before and at intervals of 6-12 months during treatment.hepatic impairment; pregnancy; breast feeding. Monitor thyroid functions on long term therapy.

Side effect: gastrointestinal disturbances including anorexia, nausea, vomiting, abdominal pain, bloating, flatulence, diarrhoea, and steatorrhoea may occur.

Postprandial glucose tolerance may be impaired and persistent hyperglycaemia occurs with chronic administration (rare). Gallstones have been reported after long-term treatment. Pain and irritation may occur at the injection site.